Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT01811524 |
| Other study ID # |
R07042 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
March 12, 2013 |
| Last updated |
March 18, 2013 |
| Start date |
September 1983 |
| Est. completion date |
March 2012 |
Study information
| Verified date |
March 2013 |
| Source |
Tampere University Hospital |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
Finland: Finnish National Agency for Medicines |
| Study type |
Observational
|
Clinical Trial Summary
The main goal of the study is to present a framework, which integrates DNA, RNA and tissue
data to identify and prioritize genetic events that represent clinically relevant new
therapeutic targets and prognostic biomarkers for different kinds of brain tumors. The
investigators study the regulation of neoplastic cell growth by oncogenes, tumor-suppressor
and other cancer related genes using modern molecular genetic methods, such as
chromogenic-in-situ hybridization, comparative genomic hybridization (CGH), array-CGH, cDNA
microarray etc. In these studies the investigators utilize disease-specific tissue
microarrays (TMA) which the investigators have constructed since 1999. Until now up to 3000
different brain tumours have been sampled to our TMA:s. These permit high-volume
simultaneous analysis of molecular targets at the DNA, mRNA and protein levels. Research
group has also focused its interest on the neoplastic development of gliomas, particularly
on their hereditary and environmental factors.
Description:
Aims of the study:
1. To collect adequate brain cancer tissue material for high throughput morphological,
protein, RNA and DNA analyses.
2. To combine tissue-related results of these analyses with clinical data to examine the
potential of the new biomarkers to assess diagnosis, prognosis and heredity of brain
tumors.
Materials and Methods
Paraffin-embedded tumor material
Paraffin blocks of more than 4,000 brain tumours have been collected into the Laboratory of
Pathology at Tampere University Hospital (Department of Pathology in Fimlab Laboratory).
They have been used primarily for purposes of clinical diagnosis, but once patient or
authority consent has been obtained the surplus of the material can be used for research
purposes. A neuropathologist has marked the most representative region of each tumour in a
tissue slide. Using these markings, tumour tissue regions are then biopsied into the tissue
microarray block (Micro-Array Technology, Beecher Instruments, Inc.). Up to 1,000
histological samples can be collected into one tissue microarray block, which can be cut
into 200 tissue sections. These sections can be used in various kinds of analysis
(immunohistochemistry, fluorescence and chromogene in situ hybridisation and other
histological standings). Among the advantages of the method are its high capacity, potential
for automation, limited damage to the original tissue block and optimised circumstances for
molecular biological analyses. We produced the first Finnish TMA block in 1999. Until now up
to 3000 different brain tumors have been sampled to our TMA:s of which 2000 gliomas and
meningiomas are used for this study. The following provides examples of projects in which
the method is used. Similar strategies are used in the present study:
1. We have studied the relationship between carbonic anhydrases and brain tumours.
Carbonic anhydrase IX (CA IX) is a hypoxia-induced enzyme that is associated with
tumorigenesis. CA IX immunopositivity was found in 80% of 362 astrocytic gliomas
collected in tissue microarray blocks. According to multifactorial survival analysis,
CA IX intensity was a significant and independent prognostic factor. CA IX is a
possible candidate for targeted therapy.
2. By using the cDNA-microarray method it is possible to analyse the expression of several
cancer genes in one hybridisation. The cDNA-CGH microarray method makes simultaneous
use of the cDNA-microarray method and comparative genomic hybridisation. This method
allows us to study the relationship between gene copy number and the expression of the
particular amplified gene, and also to define, at high resolution, the genes in cell
lines that are amplified and over- expressed. The analysis gives a more focused picture
of the relationship between changes in gene copy number and their expression in
different kinds of tumours. With these methods we have found several new cancer gene
candidates that may be involved in the pathogenesis of neuroblastomas. To ensure the
role of these genes we have built neuroblastoma tissue micro array blocks and performed
FISH and IHC analyses using these TMAs. We succeeded in characterising an amplification
region which occurred in almost half of the tumour samples of neuroblastoma patients
and which was significantly associated with patient survival.
Fresh tissue and frozen tissue microarrays
Our team at the Department of Pathology has been taking steps to prepare for molecular
biological and genetic studies that require fresh tissue archives. To this end we have
systematically collected and recorded brain tumour tissue for modern methods of cancer
diagnosis and research. The processing, storage and archiving of brain tumour tissue
from the neurosurgical operation theatres at
Tampere University Hospital are undertaken centrally at the Department of Pathology
frozen tissue laboratory. This work has been ongoing since 1992 and by now more than
1,000 fresh tumour samples have been collected. The sample material is used for exact
tumour diagnosis in the phase of primary diagnosis (e.g. genetic 1p19q LOH analysis of
oligodendrogliomas). Our novel frozen tissue application serves several new molecular
pathological methods. We have developed a completely new method based on the snap
frozen technique and produced dozens of samples from different brain localisations
(frozen brain array). The following provides one example of a project in which frozen
tissue method was used. Similar principles are to be used in the present study:
3. We have developed a new method which facilitates the differential diagnosis of brain
tumours during operation. Using the Ultrarapid Ki-67 staining method, the proliferation
marker Ki-67 can be analysed intraoperatively with the snap frozen technique and light
microscopy within 10 - 15 minutes. We were able to ascertain the applicability of the
method using frozen tissue sections of gliomas that had been previously collected into
our tissue bank. On the basis of their proliferation indices, the gliomas could be
divided into different malignancy grades and prognosis groups. This highly specific
diagnostic method can be applied for example in situations where therapeutic drugs are
placed into an intracranial operation field.
Extracted RNA and DNA
Our laboratory is well equipped and prepared for RNA and DNA studies. Following
extraction, RNA and DNA are archived and kept at -700 C for later use. Example of
projects that use this method:
4. Linkage analysis offers a powerful tool for localising genes that predispose to
familial diseases, provided that there is a sufficient number of families with the
disease concerned. For linkage analysis, the polymorphic regions of the genome are
investigated using markers of chromosomal regions that have been passed on from the
family's founder parents to all members with gliomas in the family. We have collected
blood and DNA samples from very rare glioma families (with a total of 183 members) for
purposes of linkage analysis. On the basis of genome-wide linkage analysis, we found a
new chromosome locus that was significantly associated with the familial glioma. Deep
sequencing of the samples of familial glioma patients is the following step of our
study.
Data collection
Our neuro-oncological material at the Tampere University Hospital Department of Pathology
comprises 5,000 tissue samples (4,000 paraffin and 1,000 frozen tissue samples). This is too
large a dataset to be managed by individual researchers in their own databases. Our aim
therefore is to develop a new integrated research data system for the effective management
of the tissue material that has been collected over the past 30 years, including a detailed
register on all the samples. The register will also include digital photo material from TMA
and other histological slides as well as virtual microscopy slides. The relevant clinical
data of the patients (e.g. at least three year follow-up of glioma and meningioma patients
operated during 1983 - 2009) is combined with the tissue data with the permission of Finnish
authorities and the Tampere University Hospital.
The project observes the Helsinki Declaration, current Finnish legislation and the
principles of data protection, laid down by Tampere University Hospital. This study is
retrospective and purely observational. The assignment of the medical intervention is not at
the discretion of the investigator. The collection of samples for research purposes required
each individual patient's informed consent in the familial glioma study. The archiving of
diagnostic material in a tissue bank involves no ethical problems. Only excess material from
diagnostic samples is used for research purposes, either with the patient's informed consent
or with the permission of the relevant Finnish authorities (the National Authority for
Medicolegal Affairs of Finland). The Ethical Committee of Tampere University Hospital has
given permission for our project (R07042). The familial glioma study is conducted under a
separate permit (Ministry of Social Affairs and Health , Diary number 127/08/95). Research
permits have also been obtained on the basis of the Finnish tissue law (Valvira: Diary
number 7796/05.01.00.06/2011).
